Lowest-Rated StocksLowest-RatedNYSE:SNN Smith & Nephew SNATS (SNN) Stock Price, News & Analysis $26.78 -0.72 (-2.60%) As of 12:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Smith & Nephew SNATS Stock (NYSE:SNN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Smith & Nephew SNATS alerts:Sign Up Key Stats Today's Range$26.78▼$27.2750-Day Range$27.49▼$32.6752-Week Range$26.78▼$37.51Volume917,902 shsAverage Volume1.27 million shsMarket Capitalization$11.25 billionP/E RatioN/ADividend Yield3.47%Price Target$31.91Consensus RatingHold Company Overview Smith & Nephew plc is a global medical technology company headquartered in the United Kingdom. Founded in 1856 by Thomas James Smith in Hull, the company initially operated as a pharmacy business before expanding into healthcare products and medical devices. The company develops and manufactures technologies used in orthopaedic reconstruction, sports medicine, and advanced wound management. Its products include joint replacement systems, trauma and extremities devices, arthroscopic equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products designed to support tissue healing and surgical care. Smith & Nephew serves hospitals, healthcare professionals, and patients in markets around the world. Its operations span more than 100 countries, with products marketed across North America, Europe, Asia-Pacific, and other international regions. The company’s American depositary shares trade on the New York Stock Exchange under the symbol SNN.AI Generated. May Contain Errors. Read More Smith & Nephew SNATS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreSNN MarketRank™: Smith & Nephew SNATS scored higher than 61% of companies evaluated by MarketBeat, and ranked 422nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingSmith & Nephew SNATS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 10 hold ratings, and 1 sell rating.Upside PotentialSmith & Nephew SNATS has a consensus price target of $31.91, representing about 18.2% upside from its current price of $27.00.Amount of Analyst CoverageSmith & Nephew SNATS has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Smith & Nephew SNATS's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth5.48% Earnings GrowthEarnings for Smith & Nephew SNATS are expected to grow by 5.48% in the coming year, from $2.19 to $2.31 per share.Price to Earnings Growth RatioSmith & Nephew SNATS has a PEG Ratio of 1.50. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioSmith & Nephew SNATS has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.50% of the float of Smith & Nephew SNATS has been sold short.Short Interest Ratio / Days to CoverSmith & Nephew SNATS has a short interest ratio ("days to cover") of 3.91, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Smith & Nephew SNATS has recently increased by 28.05%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldSmith & Nephew SNATS pays a meaningful dividend of 3.37%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSmith & Nephew SNATS does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 40.26% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.Read more about Smith & Nephew SNATS's dividend. News and Social Media2.9 / 5News Sentiment0.63 News SentimentSmith & Nephew SNATS has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Smith & Nephew SNATS this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Smith & Nephew SNATS to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.Percentage Held by Insiders1.00% of the stock of Smith & Nephew SNATS is held by insiders.Percentage Held by Institutions25.64% of the stock of Smith & Nephew SNATS is held by institutions.Read more about Smith & Nephew SNATS's insider trading history. Receive SNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Smith & Nephew SNATS and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNN Stock News HeadlinesMULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management6 minutes ago | globenewswire.comSmith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management56 minutes ago | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 23 at 1:00 AM | Stansberry Research (Ad)Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026September 21 at 10:00 AM | globenewswire.comIs It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says UndervaluedSeptember 14, 2026 | gurufocus.comSmith & Nephew SNATS (NYSE:SNN) Upgraded to "Buy" at Wall Street ZenSeptember 13, 2026 | americanbankingnews.comSmith & Nephew Raises $700 Million in 10‑Year U.S. Dollar NotesSeptember 12, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN) and Olema Pharmaceuticals (OLMA)August 22, 2026 | theglobeandmail.comSee More Headlines SNN Stock Analysis - Frequently Asked Questions How have SNN shares performed this year? Smith & Nephew SNATS's stock was trading at $32.81 at the beginning of 2026. Since then, SNN stock has decreased by 17.7% and is now trading at $27.0040. How were Smith & Nephew SNATS's earnings last quarter? Smith & Nephew SNATS, Inc. (NYSE:SNN) released its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.39 by $0.59. Who are Smith & Nephew SNATS's major shareholders? Top institutional shareholders of Smith & Nephew SNATS include BlackRock Inc. (1.91%), Bank of America Corp DE (0.37%), Bank of New York Mellon Corp (0.34%) and Caisse de depot et placement du Quebec (0.24%). How do I buy shares of Smith & Nephew SNATS? Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Smith & Nephew SNATS own? Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew SNATS investors own include JPMorgan Chase & Co. (JPM), Johnson & Johnson (JNJ), PepsiCo (PEP), Taiwan Semiconductor Manufacturing (TSM), McDonald's (MCD), Sanofi (SNY) and Alibaba Group (BABA). Company Calendar Last Earnings11/17/2014Today9/23/2026Record date for 11/6 Dividend10/02/2026Ex-Dividend for 11/6 Dividend10/02/2026Dividend Payable11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SNN's financial health is in the Red zone, according to TradeSmith. SNN has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:SNN CIK845982 Webwww.smith-nephew.com Phone441923477100Fax44-20-7930-3353Employees16,988Year Founded1856Price Target and Rating Average Price Target for Smith & Nephew SNATS$31.91 High Price Target$33.88 Low Price Target$30.00 Potential Upside/Downside+18.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E Ratio12.33 P/E Growth1.5Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.62 Current Ratio2.14 Quick Ratio1.11 Sales & Book Value Annual Sales$6.16 billion Price / Sales1.84 Cash Flow$3.35 per share Price / Cash Flow8.07 Book Value$12.45 per share Price / Book2.17Miscellaneous Outstanding Shares419,930,000Free Float415,730,000Market Cap$11.34 billion OptionableOptionable Beta0.55 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:SNN) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Smith & Nephew SNATS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Smith & Nephew SNATS With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
